ANIP Form 144: Proposed Sale of 6,865 Shares Valued at $616K

ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68.

Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.

Positive

• Notice filed under Rule 144 with broker identified (Morgan Stanley Smith Barney LLC)
• Full acquisition details provided: date, nature (restricted stock), and source (issuer)
• No sales in the past three months reported, clarifying recent trading activity

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice for a proposed sale of restricted shares; disclosure aligns with regulatory requirements.

The filing documents a proposed sale under Rule 144 using a registered broker, naming Morgan Stanley Smith Barney LLC, and provides required details: class, quantity, acquisition date, nature of acquisition, aggregate market value, and intended sale date. The inclusion of a statement that there have been no sales in the past three months and the standard attestation about material non-public information are consistent with standard compliance practices for insiders or restricted holders preparing to sell.

Equity Research Analyst

TL;DR: Small, disclosed sale of restricted shares; unlikely to be materially impactful to ANIP’s capitalization.

The notice specifies 6,865 shares valued at $616,223.68 and lists 21,688,772 shares outstanding, with the shares acquired from the issuer as restricted stock on 05/23/2024. The filing contains no indication of prior recent sales and does not report any unusual transaction structures. From an investor-information standpoint, this is a transparent disclosure of a planned sale rather than a material corporate event.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ANIP Form 144 report?

The filing reports a proposed sale of 6,865 common shares with an aggregate market value of $616,223.68, to be sold through Morgan Stanley Smith Barney LLC on or about 08/18/2025.

When and how were the shares acquired for this ANIP Form 144?

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date.

Does the filing indicate recent sales of ANIP shares by the filer?

The filing states Nothing to Report for securities sold during the past three months, indicating no reported recent sales.

Which exchange and broker are involved in the proposed ANIP sale?

The proposed sale is listed for NASDAQ and the broker named is Morgan Stanley Smith Barney LLC.

What statement does the filer make about material non-public information?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001819879
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ANI Pharmaceuticals, Inc.
SEC File Number	001-31812
Address of Issuer	210 Main Street West Baudette MINNESOTA 56623
Phone	(218) 634-3500
Name of Person for Whose Account the Securities are To Be Sold	JEANNE A THOMA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6865	616223.68	21688772	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/23/2024	Restricted Stock	Issuer			6865	05/23/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeanne Adele Thoma
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)